Kent Lake PR’s Myriad Genetics MYGN Stock Holding History

Kent Lake PR’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,250,000	Closed	-$6.64M	–	51
2025 Q2	$6.64M	Buy	+1,250,000	New	+$7.38M	2.93%	13

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kent Lake PR's MYGN Position: Q3 2025 in Review

Kent Lake PR sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 1,250,000 shares — an estimated $6.64M sold.

Kent Lake PR first reported a position in MYGN in Q2 2025 and held it in 1 quarter. The position peaked at $6.64M in Q2 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

Kent Lake PR reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
Kent Lake PR sold 1,250,000 Myriad Genetics shares in Q3 2025, an estimated $6.64M.
Kent Lake PR first reported a position in Myriad Genetics in Q2 2025 and held it in 1 quarter.
Kent Lake PR's Myriad Genetics position peaked at $6.64M in Q2 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Kent Lake PR's 13F filing for Q3 2025, filed 14 Nov 2025.